Control
- Published: December 10, 2020
- Last updated: December 10, 2020
The Swedish Medical Products Agency is responsible for ensuring that the development, manufacture, storage and distribution of medicinal products are carried out in such a way that patients and consumers receive medicinal products that meet the applicable requirements.
Each year, the Swedish Medical Products Agency (Swedish MPA) inspects approximately 400 pharmaceutical companies, wholesale distributors, medicinal gas installations in hospitals, blood establishments, dialysis departments, pharmacies as well as pharmaceutical manufacturers abroad.
In doing so, we have the right to receive information and documentation and to gain access to premises. This also includes the right to take photographs.
Activities under our supervision cannot be in a private dwelling.
We have supervisory responsibilities in a number of case areas, such as:
- adverse reactions
- risk of infection
- shortages of medicinal products
- deregistration, complaints
- unlawful sale
- advertising
- cost-effectiveness
- new findings, research misconduct
- abuse
- batch releases
- quality defects
- inspection of GPP, GMP, GDP, GVP and GCP.
Constant developments
The Swedish MPA is involved in the development and implementation of the national and international requirements and guidelines that are applied in the areas of supervision.
Did you benefit from the content of this page?
Contact us
Department of Drug Inspectorate – Industry and Hospital
Telephone: +46 (0)18-17 46 00
E-mail: registrator@lakemedelsverket.se